Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15(3):244‐252. doi:10.18553/jmcp.2009.15.3.244 DOI: https://doi.org/10.18553/jmcp.2009.15.3.244

Deitelzweig S, Amin A, Jing Y et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ. 2012;15(4):776-85. doi: 10.3111/13696998.2012.680555. Epub 2012 Apr 13. PMID: 22449118. DOI: https://doi.org/10.3111/13696998.2012.680555

Harder S, Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol. 2013;69(9):1617‐1633. doi:10.1007/s00228-013-1510-z DOI: https://doi.org/10.1007/s00228-013-1510-z

Barnes GD, Ageno W, Ansell J, Kaatz S; Subcommittee on the Control of Anticoagulation of the International Society on Thrombosis and Haemostasis. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. J Thromb Haemost. 2015 Jun;13(6):1154-6. doi: 10.1111/jth.12969. Erratum in: J Thromb Haemost. 2015 Aug;13(8):1539. PMID: 25880598. DOI: https://doi.org/10.1111/jth.12969

Lameijer H, Aalberts JJJ, van Veldhuisen DJ et al. Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review. Thromb Res. 2018;169:123‐127. doi:10.1016/j.thromres.2018.07.022 DOI: https://doi.org/10.1016/j.thromres.2018.07.022

Young AM, Marshall A, Thirlwall J et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018 Jul 10;36(20):2017-2023. doi: 10.1200/JCO.2018.78.8034. Epub 2018 May 10. PMID: 29746227. DOI: https://doi.org/10.1200/JCO.2018.78.8034

Agnelli G, Becattini C, Meyer G et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020 Apr 23;382(17):1599-1607. doi: 10.1056/NEJMoa1915103. Epub 2020 Mar 29. PMID: 32223112. DOI: https://doi.org/10.1056/NEJMoa1915103

Raskob GE, van Es N, Verhamme P et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 Feb 15;378(7):615-624. doi: 10.1056/NEJMoa1711948. Epub 2017 Dec 12. PMID: 29231094. DOI: https://doi.org/10.1056/NEJMoa1711948

Crowther M, Crowther MA. Antidotes for novel oral anticoagulants: current status and future potential. Arterioscler Thromb Vasc Biol. 2015;35(8):1736‐1745. doi:10.1161/ATVBAHA.114.303402 DOI: https://doi.org/10.1161/ATVBAHA.114.303402

Wanat MA. Novel oral anticoagulants: a review of new agents. Postgrad Med. 2013;125(4):103‐114. doi:10.3810/pgm.2013.07.2683 DOI: https://doi.org/10.3810/pgm.2013.07.2683

Blommel ML, Blommel AL. Dabigatran etexilate: A novel oral direct thrombin inhibitor. Am J Health Syst Pharm. 2011;68(16):1506‐1519. doi:10.2146/ajhp100348 DOI: https://doi.org/10.2146/ajhp100348

Parker K, Thachil J. The use of direct oral anticoagulants in chronic kidney disease. Br J Haematol. 2018 Oct;183(2):170-184. doi: 10.1111/bjh.15564. Epub 2018 Sep 5. PMID: 30183070. DOI: https://doi.org/10.1111/bjh.15564

Christos S, Naples R. Anticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016. West J Emerg Med. 2016 May;17(3):264-70. doi: 10.5811/westjem.2016.3.29294. Epub 2016 May 5. Erratum in: West J Emerg Med. 2016 Sep;17(5):669-70. PMID: 27330657; PMCID: PMC4899056. DOI: https://doi.org/10.5811/westjem.2016.3.29294

Pollack CV Jr, Reilly PA, van Ryn J et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med. 2017 Aug 3;377(5):431-441. doi: 10.1056/NEJMoa1707278. Epub 2017 Jul 11. PMID: 28693366. DOI: https://doi.org/10.1056/NEJMoa1707278

Connolly SJ, Ezekowitz MD, Yusuf S et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877. PMID: 19717844.

Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009 Dec 10;361(24):2342-52. doi: 10.1056/NEJMoa0906598. PMID: 19966341. DOI: https://doi.org/10.1056/NEJMoa0906598

Schulman S, Kearon C, Kakkar AK et al. RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):709-18. doi: 10.1056/NEJMoa1113697. PMID: 23425163. DOI: https://doi.org/10.1056/NEJMoa1113697

Eriksson BI, Dahl OE, Rosencher N et al. RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007 Nov;5(11):2178-85. doi: 10.1111/j.1538-7836.2007.02748.x. PMID: 17764540. DOI: https://doi.org/10.1111/j.1538-7836.2007.02748.x

Eriksson BI, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007 Sep 15;370(9591):949-56. doi: 10.1016/S0140-6736(07)61445-7. Erratum in: Lancet. 2007 Dec 15;370(9604):2004. PMID: 17869635. DOI: https://doi.org/10.1016/S0140-6736(07)61445-7

Eikelboom JW, Connolly SJ, Brueckmann M et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013 Sep 26;369(13):1206-14. doi: 10.1056/NEJMoa1300615. Epub 2013 Aug 31. PMID: 23991661. DOI: https://doi.org/10.1056/NEJMoa1300615

Aimo A, Giugliano RP, De Caterina R. Non-Vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves: Is the Door Still Open?. Circulation. 2018;138(13):1356‐1365. doi:10.1161/CIRCULATIONAHA.118.035612 DOI: https://doi.org/10.1161/CIRCULATIONAHA.118.035612

Connolly SJ, Crowther M, Eikelboom JW et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2019 Apr 4;380(14):1326-1335. doi: 10.1056/NEJMoa1814051. Epub 2019 Feb 7. PMID: 30730782; PMCID: PMC6699827.

Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10. PMID: 21830957. DOI: https://doi.org/10.1056/NEJMoa1009638

EINSTEIN Investigators, Bauersachs R, Berkowitz SD et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499‐2510. doi:10.1056/NEJMoa1007903 DOI: https://doi.org/10.1056/NEJMoa1007903

EINSTEIN–PE Investigators, Büller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287‐1297. doi:10.1056/NEJMoa1113572 DOI: https://doi.org/10.1056/NEJMoa1113572

Pengo V, Denas G, Zoppellaro G et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018 Sep 27;132(13):1365-1371. doi: 10.1182/blood-2018-04-848333. Epub 2018 Jul 12. PMID: 30002145. DOI: https://doi.org/10.1182/blood-2018-04-848333

Kakkos SK, Gohel M, Baekgaard N et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur J Vasc Endovasc Surg. 2021 Jan;61(1):9-82. doi: 10.1016/j.ejvs.2020.09.023. Epub 2020 Dec 15. PMID: 33334670. DOI: https://doi.org/10.1016/j.ejvs.2020.09.023

Eriksson BI, Borris LC, Friedman RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008 Jun 26;358(26):2765-75. doi: 10.1056/NEJMoa0800374. PMID: 18579811. DOI: https://doi.org/10.1056/NEJMoa0800374

Kakkar AK, Brenner B, Dahl OE et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008 Jul 5;372(9632):31-9. doi: 10.1016/S0140-6736(08)60880-6. Epub 2008 Jun 24. PMID: 18582928. DOI: https://doi.org/10.1016/S0140-6736(08)60880-6

Lassen MR, Ageno W, Borris LC et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008 Jun 26;358(26):2776-86. doi: 10.1056/NEJMoa076016. PMID: 18579812. DOI: https://doi.org/10.1056/NEJMoa076016

Turpie AG, Lassen MR, Davidson BL et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009 May 16;373(9676):1673-80. doi: 10.1016/S0140-6736(09)60734-0. Epub 2009 May 4. PMID: 19411100. DOI: https://doi.org/10.1016/S0140-6736(09)60734-0

Eikelboom JW, Connolly SJ, Bosch J et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27. PMID: 28844192. DOI: https://doi.org/10.1056/NEJMoa1709118

Bonaca MP, Bauersachs RM, Anand SS et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020 May 21;382(21):1994-2004. doi: 10.1056/NEJMoa2000052. Epub 2020 Mar 28. PMID: 32222135. DOI: https://doi.org/10.1056/NEJMoa2000052

Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27. PMID: 21870978. DOI: https://doi.org/10.1056/NEJMoa1107039

Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011 Mar 3;364(9):806-17. doi: 10.1056/NEJMoa1007432. Epub 2011 Feb 10. PMID: 21309657. DOI: https://doi.org/10.1056/NEJMoa1007432

Lassen MR, Raskob GE, Gallus A et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 Aug 6;361(6):594-604. doi: 10.1056/NEJMoa0810773. Erratum in: N Engl J Med. 2009 Oct 29;361(18):1814. PMID: 19657123. DOI: https://doi.org/10.1056/NEJMoa0810773

Lassen MR, Raskob GE, Gallus A et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 Mar 6;375(9717):807-15. doi: 10.1016/S0140-6736(09)62125-5. PMID: 20206776. DOI: https://doi.org/10.1016/S0140-6736(09)62125-5

Lassen MR, Gallus A, Raskob GE et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 Dec 23;363(26):2487-98. doi: 10.1056/NEJMoa1006885. PMID: 21175312. DOI: https://doi.org/10.1056/NEJMoa1006885

Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29;369(9):799-808. doi: 10.1056/NEJMoa1302507. Epub 2013 Jul 1. PMID: 23808982. DOI: https://doi.org/10.1056/NEJMoa1302507

Agnelli G, Buller HR, Cohen A et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):699-708. doi: 10.1056/NEJMoa1207541. Epub 2012 Dec 8. PMID: 23216615. DOI: https://doi.org/10.1056/NEJMoa1207541

Stacy ZA, Call WB, Hartmann AP et al. Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism. Cardiol Ther. 2016;5(1):1‐18. doi:10.1007/s40119-016-0058-2. DOI: https://doi.org/10.1007/s40119-016-0058-2

Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19. PMID: 24251359. DOI: https://doi.org/10.1056/NEJMoa1310907

Hokusai-VTE Investigators, Büller HR, Décousus H et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31. Erratum in: N Engl J Med. 2014 Jan 23;370(4):390. PMID: 23991658. DOI: https://doi.org/10.1056/NEJMoa1306638

Raskob G, Ageno W, Cohen AT et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 May;3(5):e228-36. doi: 10.1016/S2352-3026(16)00023-5. Epub 2016 Mar 22. PMID: 27132697. DOI: https://doi.org/10.1016/S2352-3026(16)00023-5

Hindricks G, Potpara T, Dagres N et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612. PMID: 32860505. DOI: https://doi.org/10.1093/eurheartj/ehaa612